Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by TD Private Client Wealth LLC

TD Private Client Wealth LLC lessened its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 11.3% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 415 shares of the company’s stock after selling 53 shares during the quarter. TD Private Client Wealth LLC’s holdings in Medpace were worth $138,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in MEDP. R Squared Ltd purchased a new position in shares of Medpace during the fourth quarter worth approximately $30,000. SBI Securities Co. Ltd. acquired a new stake in Medpace during the 4th quarter worth $31,000. Stone House Investment Management LLC purchased a new position in Medpace during the 3rd quarter worth $33,000. Jones Financial Companies Lllp increased its stake in Medpace by 2,750.0% in the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after purchasing an additional 110 shares during the period. Finally, Lindbrook Capital LLC raised its holdings in shares of Medpace by 27.6% in the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock valued at $45,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on MEDP. Leerink Partnrs raised Medpace to a “hold” rating in a report on Monday. Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Finally, Leerink Partners started coverage on Medpace in a report on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Nine investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $376.30.

Medpace Price Performance

MEDP opened at $324.51 on Wednesday. The business has a 50 day simple moving average of $337.16 and a 200-day simple moving average of $339.57. Medpace Holdings, Inc. has a 12 month low of $302.01 and a 12 month high of $459.77. The stock has a market capitalization of $9.89 billion, a P/E ratio of 25.69, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.